Proteomics Blood-Based Biomarker Discovery for ALS

Abstract

The objective to be reached upon completion of this proposal is the identification of blood-based biomarkers correlated with ALS progression and rate of progression. We will relate symptomatic clinical outcome measures from participants in our Precision Medicine Program to potential blood-based biomarkers by analyzing blood samples collected quarterly from the same participants. Clinical outcome measures used will include: 1) monthly self-assessed ALS-FRS-R measures, 2)accelerometer-based assessments of participants abilities to move their arms and legs, and 3) Machine Learning (ML)assisted, quantified assessment of speech dysarthria. Plasma samples will be analyzed using the SomaLogic SomaScan proteomics platform. Data analysis will include Machine Learning algorithms and Harvard University expert Dr. Michael Brenner.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jul 01, 2023
Accession Number
AD1208691

Entities

People

  • Fernando Vieira

Organizations

  • ALS Therapy Development Institute

Tags

Communities of Interest

  • Autonomy

DTIC Thesaurus Topics

  • Abstracts
  • Accelerometers
  • Algorithms
  • Biological Markers
  • Biomedical Research
  • Blood Donors
  • Data Analysis
  • Department Of Defense
  • Disease Attributes
  • Diseases
  • Identification
  • Information Operations
  • Instrumentation
  • Learning
  • Machine Learning
  • Maryland
  • Measuring Instruments
  • Neurobehavioral Manifestations
  • Personalized Medicine
  • Platforms
  • Precision
  • Proteomics
  • Stem Cells

Readers

  • Agent-Based Social Robotics and Mobile-Assisted Learning in Virtual Environments.
  • Life Cycle Cost Analysis
  • Oncology

Technology Areas

  • AI & ML
  • AI & ML - Neural Networks
  • Biotechnology